Drug Co. Execs Say Cost-Containment Pressures Undermine Medical Innovation
Executives such as the Bayer CEO said this kind of pressure could hamper efforts to bring new meds to market.
Reuters: Bayer CEO Decries Pressure To Lower Drug Prices
Pressure from governments to lower drug prices risks undermining medical innovation, Bayer AG's chief executive said on Wednesday, echoing complaints of other drug company executives. Speaking at the Boston College Chief Executives' Club, Marijn Dekkers said there was "tremendous pressure" on drugmakers to lower prices (Krasny, 9/19).
The Boston Globe: Executives Say Global Push To Contain Health Costs Threatens Innovation
The push to contain spiraling health costs around the world could hamper the ability of drug makers to bring new medicines to market, two biopharmaceutical executives warned Wednesday. Marijn Dekkers, chairman of German drug giant Bayer AG, sounded the alarm at a luncheon hosted by the Boston College Chief Executives' Club of Boston, saying the global economic downturn has intensified pressure to restrict reimbursements for therapeutics (Weisman, 9/19).